{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:14:23Z","timestamp":1791213263887,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ejca.2013.11.002","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T09:30:17Z","timestamp":1385717417000},"page":"611-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":245,"title":["Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct01253564","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Reinhard","family":"Dummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M.","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Turtschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina B.","family":"Eggmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lada","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Ren\u00e9","family":"Hilfiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Felderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine D.","family":"Rinderknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.11.002_b0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CMR.0b013e328352dbef","article-title":"Melanoma in the brain: biology and therapeutic options","volume":"22","author":"Gibney","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2013.11.002_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2013.11.002_b0015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.25643","article-title":"Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival","volume":"117","author":"Zakrzewski","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.11.002_b0020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0025","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/cncr.25631","article-title":"Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma","volume":"117","author":"Eigentler","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.11.002_b0030","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","article-title":"Determinants of survival in patients with brain metastases from cutaneous melanoma","volume":"102","author":"Staudt","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2013.11.002_b0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000076903","article-title":"Survival and prognostic factors in patients with brain metastases from malignant melanoma","volume":"27","author":"Meier","year":"2004","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2013.11.002_b0040","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.11.002_b0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0167-8140(92)90329-S","article-title":"Cerebral metastases from malignant melanoma","volume":"23","author":"Stevens","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/PPO.0b013e31824b2890","article-title":"Treatment of melanoma brain metastases: a new paradigm","volume":"18","author":"Carlino","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.ejca.2013.11.002_b0055","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2013.11.002_b0060","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2013.11.002_b0065","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated braf in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.11.002_b0070","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0075","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"Brim 2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600e mutation-positive metastatic melanoma","volume":"29","author":"Ribas","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAFV600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.11.002_b0085","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with braf v600e mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.11.002_b0090","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8502","article-title":"Updated overall survival (OS) results from BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DITC) in previously untreated patients with BRAFV600E-mutated melanoma","volume":"30","author":"Chapman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0095","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2013.11.002_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8548","article-title":"An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases","volume":"29","author":"Dummer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S1470-2045(12)70118-3","article-title":"Treatment of brain metastases in patients with melanoma","volume":"13","author":"Fisher","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(09)70389-4","article-title":"Whole-brain irradiation for patients with brain metastases: still the standard of care","volume":"11","author":"Mahmood","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","volume":"31","author":"Soffietti","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0125","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.11.002_b0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00213-003-1540-9","article-title":"Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers","volume":"170","author":"Zacny","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejca.2013.11.002_b0135","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1523\/JNEUROSCI.14-04-02047.1994","article-title":"Glucocorticoid-induced impairment in declarative memory performance in adult humans","volume":"14","author":"Newcomer","year":"1994","journal-title":"J Neurosci"},{"issue":"Suppl. 7","key":"10.1016\/j.ejca.2013.11.002_b0140","doi-asserted-by":"crossref","first-page":"vii86","DOI":"10.1093\/annonc\/mds229","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Dummer","year":"2012","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913009799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913009799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T21:59:47Z","timestamp":1597096787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913009799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0959804913009799"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.11.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718196703.793501048","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2013.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}